Carbohydrate-protein conjugate vaccines

Clinical Microbiology and Infection

Volumn 9, Issue 2, 2003, Pages 79-85

  Ada, G ^a   Isaacs, D ^b  

^a Biology and Environment   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Antibody; Carbohydrate; Immune response; Protein; Vaccination; Vaccine

Indexed keywords

CARRIER PROTEIN; CHOLERA TOXIN B SUBUNIT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; DRUG CARRIER; EPITOPE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN M; MENINGITIS VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PNEUMOCOCCUS VACCINE; POLYRIBOSYL RIBITOL PHOSPHATE; POLYSACCHARIDE; POLYSACCHARIDE VACCINE; PROTEIN; PSEUDOMONAS EXOTOXIN; SALMONELLOSIS VACCINE; STREPTOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY PRODUCTION; BACTERIAL MEMBRANE; CHRONOTHERAPY; CLINICAL TRIAL; DRUG COMPETITION; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; SALMONELLA TYPHI; SALMONELLOSIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINE PRODUCTION;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE SEROTYPE B; NEISSERIA; NEISSERIA MENINGITIDIS; PSEUDOMONAS; SALMONELLA; SALMONELLA TYPHI; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0038752905     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00530.x     Document Type: Review

References (45)

1. Landsteiner K. The specificity of serological reactions. Cambridge: Harvard University Press, 1945.
2. Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate proteins. II. Immunological specificity of synthetic sugar protein antigen. J Exp Med 1929; 50: 533-50.
3. Lindberg AA. Glycoprotein conjugate vaccines. Vaccine 1999; 17: S28-36.
4. Stein KE. Thymus-independent and thymus-dependent response to polysaccharide antigens. J Infect Dis 1992; 165(suppl 1): S49-52.
5. Ward JI, Zangwill KM. Haemophilus influenzae vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines, 3rd edn. Philadelphia: WB Saunders, 1999: 183-221.
6. Baker PJ. T cell regulation of the antibody response to bacterial polysaccharide antigens: an examination of some general characteristics and their implications. J Infect Dis 1992; 165(suppl): S44-8.
7. Breukels MA, Zandvoort A, Van Den Dobblesteen GP et al. Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides. Infect Immun 2001; 69: 7583-7.
8. Rodrigo M-J, Miravitlles M, Cruz M-J et al. Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneurnococcal vaccine in a healthy adult population: proposal for response criteria. Clin Diagn Lab Immunol 1997; 4: 168-72.
9. Mattern TF, Hans-Dieter L, Brade ET et al. Stimulation of human T lymphocytes by LPS is MHC-non-restricted but strongly dependent on B7 interactions. J Immunol 1998; 160: 3412-16.
10. Born W, Cady C, Jones-Carson J et al. Immunoregulatory functions of γ,δT cells. Adv Immunol 1999; 71: 77-124.
11. Hayday AC. γ,δ Cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18: 975-1026.
12. Noelle RJ, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B cell activation. Immunol Today 1992; 13: 431-3.
13. Hasbold J, Lyons AB, Kehry MR, Hodgkin PD. Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4. Eur J Immunol 1998; 28: 1040-51.
14. Weinberg GA, Granoff DM. Immunogenicity to Haemophilus influenzae type b conjugate vaccines in children with conditions associated with impaired antibody responses to type b polysaccharide vaccine. Pediatrics 1990; 85: 654-61.
15. Kayhty H, Peltola H, Karanlo V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 47: 1100-1.
16. Peltola H, Kayhty H, Sivonen A. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field trial of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60: 730-7.
17. Adams WG, Deaver KA, Cochi SL et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993; 269: 221-6.
18. Goldblatt D, Pinto Vaz AJPM, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998; 177: 1112-15.
19. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340: 592-4.
20. Schuchat A, Robinson K, Wenger JD et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337: 970-6.
21. Takala AK, Escola J, Lievonen M. Reduction of oropharyngeal carriage of the Haemophilus influenzae type b (Hib) in children immunised with an Hib conjugate vaccine. J Infect Dis 1991; 164: 982-6.
22. Barbour ML, Mayon-White RT, Coles C, Crook DWM, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995; 171: 93-8.
23. Booy R, Heath PT, Slack MPE, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type b. Lancet 1997; 349: 1197-202.
24. Jonsdotir KE, Steingrimsson O, Olafsson O. Immunisation of infants in Iceland against Haemophilus influenzae type b. Lancet 1992; 340: 252-3.
25. Eskola J, Kayhty H. Pneumococcal vaccines. Clin Paediatr 1997; 5: 101-20.
26. Robbins JB, Austrian R, Lee CJ. Consideration for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148: 1136-59.
27. Lievonen M, Sakkinen A, Kalliokoshi R. Antibody response to pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis 1986; 5: 39-44.
28. Black S, Shinefeld H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2000; 19: 187-95.
29. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against otitis media. N Engl J Med 2001; 344: 403-9.
30. Makela PH, Peltola H, Kayhty H. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1996; 174: 1360-3.
31. Leach A, Twumasi PA, Kumah S et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997; 175: 200-4.
32. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers. A randomized controlled trial. JAMA 1998; 280: 1685-9.
33. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195-6.
34. Kossaczkz Z, Lin FY, Ho VA et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999; 67: 5806-10.
35. Lin FYC, Vo AH, Khiem HB et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to five-year-old children. N Engl J Med 2001; 344: 1263-9.
36. Baker CJ, Rench MA, Edwards MS et al. Immunisation of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med 1988; 319: 1180-5.
37. Wessels MR, Paoletti LC, Guttormsen HK et al. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect Immun 1998; 66: 2186-92.
38. Shen X, Lagergard T, Yang Y et al. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Vaccine 2000; 19: 850-61.
39. Marques MB, Kasper DI, Shroff A et al. Functional antibodies to the group B streptococci elicited by a polysaccharide-protein conjugate vaccine. Infect Immun 1994; 62: 1593-9.
40. Baker CJ, Paoletti LC, Rench MA et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. J Infect Dis 2000; 182: 1129-38.
41. Fattom AI, Sarwar J, Basham L et al. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines. Infect Immun 1998; 66: 4588-92.
42. Fattom A, Li X, Cho YH et al. Effect of conjugation methodology, carrier protein and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine 1995; 13: 1288-93.
43. Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346: 491-6.
44. Cryz SR Jr, Que JO, Cross S, Furer E. Synthesis and characterization of a polyvalent Escherichia coli Opolysaccharide-toxin A conjugate vaccine. Vaccine 1995; 13: 449-53.
45. Daum RS, Zenko CE, Given GZ et al. Magnitude of interference after diphtheria-tetanus-acellular pertussis/H. influenzae type b capsular polysaccharidetetanus vaccination is related to the number of doses administered. J Infect Dis 2001; 184: 1293-9.